GlobeStar Therapeutics Corp: 10-Q filed 2014-05-20
What GlobeStar Therapeutics Corp reported in its quarterly report filed 2014-05-20 (fiscal Q2 2014): 21 published measures, 58 facts as tagged in accession 0001161697-14-000205.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2014-05-20
- Fiscal period
- fiscal Q2 2014
- Accession
- 0001161697-14-000205 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All GlobeStar Therapeutics Corp filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 411,512 | USD | |
| At 2013-09-30 | 462,558 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 565,712 | USD | |
| At 2013-09-30 | 217,276 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | -154,200 | USD | |
| At 2013-09-30 | 245,282 | USD | |
| At 2012-09-30 | -106,134 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 91,107 | USD | |
| At 2013-09-30 | 127,748 | USD | |
| At 2013-03-31 | 34,487 | USD | |
| At 2012-09-30 | 1,359 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -181,562 | USD | 90 |
| 2013-10-01 to 2014-03-31 | -562,083 | USD | 182 |
| 2012-10-01 to 2013-09-30 | -945,111 | USD | 365 |
| 2013-01-01 to 2013-03-31 | -235,893 | USD | 90 |
| 2012-10-01 to 2013-03-31 | -331,900 | USD | 182 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-03-31 | -200,952 | USD | 182 |
| 2012-10-01 to 2013-03-31 | -121,847 | USD | 182 |
Revenue
Revenue under this specific accounting concept. A missing value is not zero; filers can use other revenue concepts.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 21,859 | USD | 90 |
| 2013-10-01 to 2014-03-31 | 54,069 | USD | 182 |
| 2013-01-01 to 2013-03-31 | 13,750 | USD | 90 |
| 2012-10-01 to 2013-03-31 | 37,707 | USD | 182 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-03-31 | 203,980 | USD | 182 |
| 2012-10-01 to 2013-03-31 | 241,015 | USD | 182 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-03-31 | -39,669 | USD | 182 |
| 2012-10-01 to 2013-03-31 | -86,040 | USD | 182 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | -2,673,687 | USD | |
| At 2013-09-30 | -2,111,605 | USD |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | -114,801 | USD | 90 |
| 2013-10-01 to 2014-03-31 | -299,724 | USD | 182 |
| 2013-01-01 to 2013-03-31 | -135,294 | USD | 90 |
| 2012-10-01 to 2013-03-31 | -194,438 | USD | 182 |
Current assets
Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 113,120 | USD | |
| At 2013-09-30 | 138,206 | USD |
Interest expense
Borrowing costs recognized as interest expense. This is distinct from cash interest paid and may not include every capitalized borrowing cost.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 66,761 | USD | 90 |
| 2013-10-01 to 2014-03-31 | 262,359 | USD | 182 |
| 2013-01-01 to 2013-03-31 | 100,599 | USD | 90 |
| 2012-10-01 to 2013-03-31 | 137,462 | USD | 182 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 369,209 | USD | |
| At 2013-09-30 | 121,058 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 157,729 | USD | |
| At 2013-09-30 | 113,558 | USD |
Net current accounts receivable
Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 22,013 | USD | |
| At 2013-09-30 | 10,458 | USD |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 14,813,730 | shares | |
| At 2013-09-30 | 10,863,730 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2014-03-31 | 2,518,006 | USD | |
| At 2013-09-30 | 2,355,801 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 111,245 | USD | 90 |
| 2013-10-01 to 2014-03-31 | 276,313 | USD | 182 |
| 2013-01-01 to 2013-03-31 | 146,508 | USD | 90 |
| 2012-10-01 to 2013-03-31 | 224,289 | USD | 182 |
Depreciation, depletion and amortization
Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2014-01-01 to 2014-03-31 | 7,730 | USD | 90 |
| 2013-10-01 to 2014-03-31 | 30,630 | USD | 182 |
| 2013-01-01 to 2013-03-31 | 2,202 | USD | 90 |
| 2012-10-01 to 2013-03-31 | 7,206 | USD | 182 |
Change in accounts receivable
The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2013-10-01 to 2014-03-31 | 11,555 | USD | 182 |
| 2012-10-01 to 2013-03-31 | 13,984 | USD | 182 |
Inspect the source
- Entity
- GlobeStar Therapeutics Corp / CIK 0001502152
- Captured
- 2026-09-21T17:19:31.788Z
- SEC response SHA-256
6be36a03e8f75354b6b3cf653d7b4e1bb0d8a85378e8b575eedf967d0fac66f7
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001502152.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))